269 related articles for article (PubMed ID: 27793097)
1. Myocardial lipid content in Fabry disease: a combined
Petritsch B; Köstler H; Weng AM; Horn M; Gassenmaier T; Kunz AS; Weidemann F; Wanner C; Bley TA; Beer M
BMC Cardiovasc Disord; 2016 Oct; 16(1):205. PubMed ID: 27793097
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive determination of myocardial lipid content in Fabry disease by 1H-MR spectroscopy.
Petritsch B; Köstler H; Machann W; Horn M; Weng AM; Goltz JP; Hahn D; Niemann M; Weidemann F; Wanner C; Beer M
Rofo; 2012 Nov; 184(11):1020-5. PubMed ID: 22893488
[TBL] [Abstract][Full Text] [Related]
3. Global longitudinal strain, myocardial storage and hypertrophy in Fabry disease.
Vijapurapu R; Nordin S; Baig S; Liu B; Rosmini S; Augusto J; Tchan M; Hughes DA; Geberhiwot T; Moon JC; Steeds RP; Kozor R
Heart; 2019 Mar; 105(6):470-476. PubMed ID: 30282640
[TBL] [Abstract][Full Text] [Related]
4. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment.
Niemann M; Herrmann S; Hu K; Breunig F; Strotmann J; Beer M; Machann W; Voelker W; Ertl G; Wanner C; Weidemann F
JACC Cardiovasc Imaging; 2011 Jun; 4(6):592-601. PubMed ID: 21679893
[TBL] [Abstract][Full Text] [Related]
5. Proposed Stages of Myocardial Phenotype Development in Fabry Disease.
Nordin S; Kozor R; Medina-Menacho K; Abdel-Gadir A; Baig S; Sado DM; Lobascio I; Murphy E; Lachmann RH; Mehta A; Edwards NC; Ramaswami U; Steeds RP; Hughes D; Moon JC
JACC Cardiovasc Imaging; 2019 Aug; 12(8 Pt 2):1673-1683. PubMed ID: 29778854
[TBL] [Abstract][Full Text] [Related]
6. Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study.
Weidemann F; Beer M; Kralewski M; Siwy J; Kampmann C
Mol Genet Metab; 2019 Feb; 126(2):169-182. PubMed ID: 30594474
[TBL] [Abstract][Full Text] [Related]
7. Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy.
Nordin S; Kozor R; Vijapurapu R; Augusto JB; Knott KD; Captur G; Treibel TA; Ramaswami U; Tchan M; Geberhiwot T; Steeds RP; Hughes DA; Moon JC
Circ Cardiovasc Imaging; 2019 Dec; 12(12):e009430. PubMed ID: 31826677
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Involvement in Myotonic Dystrophy Type 2 Patients With Preserved Ejection Fraction: Detection by Cardiovascular Magnetic Resonance.
Schmacht L; Traber J; Grieben U; Utz W; Dieringer MA; Kellman P; Blaszczyk E; von Knobelsdorff-Brenkenhoff F; Spuler S; Schulz-Menger J
Circ Cardiovasc Imaging; 2016 Jul; 9(7):. PubMed ID: 27363857
[TBL] [Abstract][Full Text] [Related]
9. Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease.
Krämer J; Niemann M; Störk S; Frantz S; Beer M; Ertl G; Wanner C; Weidemann F
Am J Cardiol; 2014 Sep; 114(6):895-900. PubMed ID: 25073565
[TBL] [Abstract][Full Text] [Related]
10. Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease.
Augusto JB; Nordin S; Vijapurapu R; Baig S; Bulluck H; Castelletti S; Alfarih M; Knott K; Captur G; Kotecha T; Ramaswami U; Tchan M; Geberhiwot T; Fontana M; Steeds RP; Hughes D; Kozor R; Moon JC
Circ Cardiovasc Imaging; 2020 Mar; 13(3):e010171. PubMed ID: 32114828
[TBL] [Abstract][Full Text] [Related]
11. Myocardial fibrosis imaging based on T1-mapping and extracellular volume fraction (ECV) measurement in muscular dystrophy patients: diagnostic value compared with conventional late gadolinium enhancement (LGE) imaging.
Florian A; Ludwig A; Rösch S; Yildiz H; Sechtem U; Yilmaz A
Eur Heart J Cardiovasc Imaging; 2014 Sep; 15(9):1004-12. PubMed ID: 24686257
[TBL] [Abstract][Full Text] [Related]
12. Tei index in fabry disease.
Niemann M; Breunig F; Beer M; Hu K; Liu D; Emmert A; Herrmann S; Ertl G; Wanner C; Takenaka T; Tei C; Weidemann F
J Am Soc Echocardiogr; 2011 Sep; 24(9):1026-32. PubMed ID: 21719255
[TBL] [Abstract][Full Text] [Related]
13. Myocardial fibrosis as the first sign of cardiac involvement in a male patient with Fabry disease: report of a clinical case and discussion on the utility of the magnetic resonance in Fabry pathology.
Sechi A; Nucifora G; Piccoli G; Dardis A; Bembi B
BMC Cardiovasc Disord; 2014 Jul; 14():86. PubMed ID: 25026990
[TBL] [Abstract][Full Text] [Related]
14. Myocardial Fibrosis and Left Ventricular Dysfunction in Duchenne Muscular Dystrophy Carriers Using Cardiac Magnetic Resonance Imaging.
Lang SM; Shugh S; Mazur W; Sticka JJ; Rattan MS; Jefferies JL; Taylor MD
Pediatr Cardiol; 2015 Oct; 36(7):1495-501. PubMed ID: 25976773
[TBL] [Abstract][Full Text] [Related]
15. Cardiac Phenotype of Prehypertrophic Fabry Disease.
Nordin S; Kozor R; Baig S; Abdel-Gadir A; Medina-Menacho K; Rosmini S; Captur G; Tchan M; Geberhiwot T; Murphy E; Lachmann R; Ramaswami U; Edwards NC; Hughes D; Steeds RP; Moon JC
Circ Cardiovasc Imaging; 2018 Jun; 11(6):e007168. PubMed ID: 29853467
[TBL] [Abstract][Full Text] [Related]
16. Correlation between extent of myocardial fibrosis assessed by cardiac magnetic resonance and cardiac troponin T release in patients with nonischemic heart failure.
Takashio S; Yamamuro M; Uemura T; Utsunomiya D; Morita K; Izumiya Y; Sugiyama S; Kojima S; Yamamoto E; Tsujita K; Tanaka T; Tayama S; Kaikita K; Hokimoto S; Yasuda O; Yamashita Y; Ogawa H
Am J Cardiol; 2014 May; 113(10):1697-704. PubMed ID: 24698466
[TBL] [Abstract][Full Text] [Related]
17. [MR imaging and MR spectroscopy for characterization of cardiomyopathies in adolescents - preliminary results].
Beer M; Buchner S; Wirbelauer J; Fuchs J; Machann W; Ritter CO; Beissert M; Darge K; Hahn D; Köstler H
Rofo; 2007 Sep; 179(9):932-7. PubMed ID: 17705115
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Compacted Myocardial Abnormalities by Cardiac Magnetic Resonance With Native T1 Mapping in Left Ventricular Non-Compaction Patients - A Comparison With Late Gadolinium Enhancement.
Zhou H; Lin X; Fang L; Zhao X; Ding H; Chen W; Xu R; Bai X; Wang Y; Fang Q
Circ J; 2016 Apr; 80(5):1210-6. PubMed ID: 27010628
[TBL] [Abstract][Full Text] [Related]
19. T₁ mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex.
Thompson RB; Chow K; Khan A; Chan A; Shanks M; Paterson I; Oudit GY
Circ Cardiovasc Imaging; 2013 Sep; 6(5):637-45. PubMed ID: 23922004
[TBL] [Abstract][Full Text] [Related]
20. Role of cardiac imaging in Anderson-Fabry cardiomyopathy.
Serra W; Marziliano N
Cardiovasc Ultrasound; 2019 Jan; 17(1):1. PubMed ID: 30674321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
